<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly â€” Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly</h2>
    <div class="badge">2025-09-15T12:44:22+00:00</div>
    <ul>
      <li>Sep 15 - Novo Nordisk (NYSE:NVO) reported that a higher semaglutide dose helped patients lose more weight in two late-stage trials, and its Copenhagen-listed shares rose about 1.5%.</li>
<li>The trials tested a 7.2 mg dose, three times the approved 2.4 mg, and measured weight change over 72 weeks.</li>
<li>Eli Lilly (NYSE:LLY) posted stronger headline results with tirzepatide, achieving up to 22.5 percent weight loss at its top dose, keeping competition tight.Observers said the incremental gains for semaglutide matter, esp</li>
<li>This article first appeared on GuruFocus.</li>
<li>In the larger study, participants on 7.2 mg lost an average of 19 percent of body weight, compared with about 16 percent on 2.4 mg and 4 percent on placebo.</li>
<li>Novo has faced setbacks in the U.S., including market share losses and a roughly 60 percent share decline over the past year as it trims its global workforce.</li>
<li>The data may strengthen Novo&#x27;s case for higher-dose strategies if regulators and payers accept the approach.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Novo%20Nordisk%20Shares%20Rise%20as%20Obesity%20Trial%20Results%20Narrow%20Gap%20With%20Eli%20Lilly%0A%E2%80%A2%20Sep%2015%20-%20Novo%20Nordisk%20%28NYSE%3ANVO%29%20reported%20that%20a%20higher%20semaglutide%20dose%20helped%20patients%20lose%20more%20weight%20in%20two%20late-stage%20trials%2C%20and%20its%20Copenhagen-listed%20shares%20rose%20about%201.5%25.%0A%E2%80%A2%20The%20trials%20tested%20a%207.2%20mg%20dose%2C%20three%20times%20the%20approved%202.4%20mg%2C%20and%20measured%20weight%20change%20over%2072%20weeks.%0A%E2%80%A2%20Eli%20Lilly%20%28NYSE%3ALLY%29%20posted%20stronger%20headline%20results%20with%20tirzepatide%2C%20achieving%20up%20to%2022.5%20percent%20weight%20loss%20at%20its%20top%20dose%2C%20keeping%20competition%20tight.Observers%20said%20the%20incremental%20gains%20for%20semaglutide%20matter%2C%20esp%0A%E2%80%A2%20This%20article%20first%20appeared%20on%20GuruFocus.%0A%E2%80%A2%20In%20the%20larger%20study%2C%20participants%20on%207.2%20mg%20lost%20an%20average%20of%2019%20percent%20of%20body%20weight%2C%20compared%20with%20about%2016%20percent%20on%202.4%20mg%20and%204%20percent%20on%20placebo.%0A%E2%80%A2%20Novo%20has%20faced%20setbacks%20in%20the%20U.S.%2C%20including%20market%20share%20losses%20and%20a%20roughly%2060%20percent%20share%20decline%20over%20the%20past%20year%20as%20it%20trims%20its%20global%20workforce.%0A%E2%80%A2%20The%20data%20may%20strengthen%20Novo%27s%20case%20for%20higher-dose%20strategies%20if%20regulators%20and%20payers%20accept%20the%20approach.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fnovo-nordisk-shares-rise-as-obesity-trial-results-narrow-gap-with-eli-lilly%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/novo-nordisk-shares-rise-obesity-124422607.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>